MedTrace Logo

Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients

NCT02327689 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2014-12-30

No results posted yet for this study

Summary

This study evaluates generic emtricitabine(FTC) plus adefovir dipivoxil in Chinese naive HBV related cirrhosis patients. Patients were divided into 2 groups: compensated HBV related cirrhosis patients and decompensated HBV related cirrhosis patients.

Conditions

Interventions

DRUG

Emtricitabine plus adefovir dipivoxil

emtricitabine plus adefovir dipivoxil were given to each patients for 96 weeks

Sponsors & Collaborators

  • Beijing Ditan Hospital

    collaborator OTHER

  • Hebei Medical University Pharmaceutical Factory

    collaborator INDUSTRY

  • National Health and Family Planning Commission, P.R.China

    collaborator OTHER_GOV

  • Asian-Pacific Alliance of Liver Disease, Beijing

    lead OTHER

Principal Investigators

  • Jun Cheng, M.D. · Asian Pacific Alliance of Liver Diseases, Beijing

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2015-07-31
Completion
2017-07-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02327689 on ClinicalTrials.gov